<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>7565338</pmcid><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pmid">33066822</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pmc">7565338</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="publisher-id">355</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="doi">10.1186/s40644-020-00355-6</article-id></all-ids><extracted-table><table-id>Tab1</table-id><table-label>Table 1</table-label><table-caption>Demographic, Clinical, and Neuropsychological Data at Baseline</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table 1</label><caption><p>Demographic, Clinical, and Neuropsychological Data at Baseline</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variables</th><th>BC group (<italic>n</italic> = 17)</th><th>HC group(<italic>n</italic> = 19)</th><th><italic>P</italic> value</th></tr></thead><tbody><tr><td colspan="4"><bold>Age (years)</bold></td></tr><tr><td> median ± (IQRs)</td><td>46 (40–50)</td><td>47 (36–52)</td><td>0.505<sup>c</sup></td></tr><tr><td colspan="4"><bold>Education levels (years)</bold></td></tr><tr><td> median ± (IQRs)</td><td>12 (9–14)</td><td>15 (11–16)</td><td>0.065<sup>c</sup></td></tr><tr><td><bold>Premenopause, n (%)</bold></td><td>11 (64.7)</td><td>11 (57.9)</td><td>0.896<sup>b</sup></td></tr><tr><td><bold>Menopause, n (%)</bold></td><td>6 (35.3)</td><td>8 (42.1)</td><td>0.734<sup>b</sup></td></tr><tr><td colspan="4"><bold>Breast cancer stage, n (%)</bold></td></tr><tr><td> I</td><td>4 (23.5)</td><td>NA</td><td>NA</td></tr><tr><td> II</td><td>7 (41.2)</td><td>NA</td><td>NA</td></tr><tr><td> III</td><td>6 (35.3)</td><td>NA</td><td>NA</td></tr><tr><td><bold>Chemotherapy regimen stage (I-III)</bold></td><td/><td>NA</td><td>NA</td></tr><tr><td colspan="2"> Postoperative chemotherapy, (I-III)</td><td/><td/></tr><tr><td> AC-T (eight cycles), n (%)</td><td>11 (64.7)</td><td>NA</td><td>NA</td></tr><tr><td colspan="2"> Neoadjuvant chemotherapy, (I-III)</td><td/><td/></tr><tr><td> TEC (six cycles), n (%)</td><td>5 (29.4)</td><td>NA</td><td>NA</td></tr><tr><td> AC-T (eight cycles), (IIB)</td><td>1 (5.9)</td><td/><td/></tr><tr><td colspan="4"><bold>Clinical data, median ± (IQRs)</bold></td></tr><tr><td> SAS (score)</td><td>29.0 (27.0–31.75)</td><td>25.0 (22.8–26.0)</td><td>0.012<sup>c</sup></td></tr><tr><td> SDS (score)</td><td>27.5 (24.5–32.0)</td><td>23.0 (22.0–27.0)</td><td>0.002<sup>c</sup></td></tr><tr><td> E2 (pmol/L)</td><td>265.0 (112.3–391.8)</td><td>83.0 (42.0–199.0)</td><td>0.220<sup>c</sup></td></tr><tr><td> FSH (IU/L)</td><td>6.9 (3.9–40.1)</td><td>26.8 (8.1–80.3)</td><td>0.021<sup>a</sup></td></tr><tr><td> LH (IU/L)</td><td>7.3 (2.2–25.4)</td><td>21.6 (8.3–40.6)</td><td>0.501<sup>c</sup></td></tr><tr><td> Hemoglobin(g/L)</td><td>124.0 (110.0–134.0)</td><td>131.0 (125.0–136.0)</td><td>0.334<sup>c</sup></td></tr><tr><td> Total cholesterol (mmol/L)</td><td>4.9 (4.3–5.7)</td><td>5.2 (4.5–5.7)</td><td>0.037<sup>c</sup></td></tr><tr><td> Triglycerides (mmol/L)</td><td>1.5 (0.9–3.0)</td><td>0.8 (0.6–1.7)</td><td>0.030<sup>c</sup></td></tr><tr><td> Fasting glucose (mmol/L)</td><td>5.2 (4.7–7.2)</td><td>4.9 (4.6–5.2)</td><td>0.005<sup>a</sup></td></tr><tr><td colspan="4"><bold>Cognitive performance, median ± (IQRs)</bold></td></tr><tr><td> MMSE (score)</td><td>28.0 (27.0–29.5)</td><td>29.0 (28.0–30.0)</td><td>0.061c</td></tr><tr><td> DST (score)</td><td>49.5 (34.0–61.8)</td><td>62.0 (45.0–69.0)</td><td>0.408<sup>c</sup></td></tr><tr><td> LTT (sec)</td><td>59.8 (46.1–83.2)</td><td>32.3 (24.2–38.1)</td><td>0.429<sup>c</sup></td></tr><tr><td> SDT (sec)</td><td>37.5 (33.3–42.3)</td><td>30.7 (27.1–34.5)</td><td>0.050<sup>a</sup></td></tr><tr><td> WDT (score)</td><td>24.0 (22.0–27.0)</td><td>27.0 (24.5–29.3)</td><td>0.010<sup>a</sup></td></tr><tr><td> Stroop-C (sec)</td><td>15.3 (13.5–18.4)</td><td>13.8 (9.9–15.8)</td><td>0.005<sup>a</sup></td></tr><tr><td> Stroop-W (sec)</td><td>22.0 (18.5–26.1)</td><td>16.0 (13.5–18.5)</td><td>&lt; 0.001<sup>c</sup></td></tr><tr><td> Stroop-I (sec)</td><td>31.5 (24.9–33.0)</td><td>24.3 (19.2–28.4)</td><td>0.003<sup>c</sup></td></tr></tbody></table><table-wrap-foot><p>a: k-independent samples nonparametric tests; b: chi square test; c: two-sample t test</p><p><italic>Abbreviations</italic>: <italic>A</italic> Doxorubicin, <italic>C</italic> Cyclophosphamide, <italic>T</italic> Docetaxel, <italic>E</italic> Epirubicin, <italic>SD</italic> standard deviation, <italic>E2</italic> estradiol, <italic>FSH</italic> follicle stimulating hormone, <italic>LH</italic> luteinizing hormone, <italic>DST</italic> digit symbol test, <italic>MMSE</italic> Mini-mental state examination, <italic>LTT</italic> line tracing test, <italic>NCT-A</italic> number connection test A, <italic>SDT</italic> serial dotting test, <italic>SDS</italic> Self-Rating Depression Scale, <italic>SAS</italic> Self-Rating Anxiety Scale, <italic>Stroop-C</italic> Stroop colour test, <italic>Stroop-D</italic> Stroop word test, <italic>Stroop-I</italic> Stroop interference test, <italic>WDT</italic> Auditory verbal learning memory</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Demographic, Clinical, and Neuropsychological Data at Baseline</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th>Variables</th><th>BC group (n = 17)</th><th>HC group(n = 19)</th><th>P value</th></tr></thead><tbody><tr><td colspan="4">Age (years)</td></tr><tr><td> median ± (IQRs)</td><td>46 (40–50)</td><td>47 (36–52)</td><td>0.505c</td></tr><tr><td colspan="4">Education levels (years)</td></tr><tr><td> median ± (IQRs)</td><td>12 (9–14)</td><td>15 (11–16)</td><td>0.065c</td></tr><tr><td>Premenopause, n (%)</td><td>11 (64.7)</td><td>11 (57.9)</td><td>0.896b</td></tr><tr><td>Menopause, n (%)</td><td>6 (35.3)</td><td>8 (42.1)</td><td>0.734b</td></tr><tr><td colspan="4">Breast cancer stage, n (%)</td></tr><tr><td> I</td><td>4 (23.5)</td><td>NA</td><td>NA</td></tr><tr><td> II</td><td>7 (41.2)</td><td>NA</td><td>NA</td></tr><tr><td> III</td><td>6 (35.3)</td><td>NA</td><td>NA</td></tr><tr><td>Chemotherapy regimen stage (I-III)</td><td/><td>NA</td><td>NA</td></tr><tr><td colspan="2"> Postoperative chemotherapy, (I-III)</td><td/><td/></tr><tr><td> AC-T (eight cycles), n (%)</td><td>11 (64.7)</td><td>NA</td><td>NA</td></tr><tr><td colspan="2"> Neoadjuvant chemotherapy, (I-III)</td><td/><td/></tr><tr><td> TEC (six cycles), n (%)</td><td>5 (29.4)</td><td>NA</td><td>NA</td></tr><tr><td> AC-T (eight cycles), (IIB)</td><td>1 (5.9)</td><td/><td/></tr><tr><td colspan="4">Clinical data, median ± (IQRs)</td></tr><tr><td> SAS (score)</td><td>29.0 (27.0–31.75)</td><td>25.0 (22.8–26.0)</td><td>0.012c</td></tr><tr><td> SDS (score)</td><td>27.5 (24.5–32.0)</td><td>23.0 (22.0–27.0)</td><td>0.002c</td></tr><tr><td> E2 (pmol/L)</td><td>265.0 (112.3–391.8)</td><td>83.0 (42.0–199.0)</td><td>0.220c</td></tr><tr><td> FSH (IU/L)</td><td>6.9 (3.9–40.1)</td><td>26.8 (8.1–80.3)</td><td>0.021a</td></tr><tr><td> LH (IU/L)</td><td>7.3 (2.2–25.4)</td><td>21.6 (8.3–40.6)</td><td>0.501c</td></tr><tr><td> Hemoglobin(g/L)</td><td>124.0 (110.0–134.0)</td><td>131.0 (125.0–136.0)</td><td>0.334c</td></tr><tr><td> Total cholesterol (mmol/L)</td><td>4.9 (4.3–5.7)</td><td>5.2 (4.5–5.7)</td><td>0.037c</td></tr><tr><td> Triglycerides (mmol/L)</td><td>1.5 (0.9–3.0)</td><td>0.8 (0.6–1.7)</td><td>0.030c</td></tr><tr><td> Fasting glucose (mmol/L)</td><td>5.2 (4.7–7.2)</td><td>4.9 (4.6–5.2)</td><td>0.005a</td></tr><tr><td colspan="4">Cognitive performance, median ± (IQRs)</td></tr><tr><td> MMSE (score)</td><td>28.0 (27.0–29.5)</td><td>29.0 (28.0–30.0)</td><td>0.061c</td></tr><tr><td> DST (score)</td><td>49.5 (34.0–61.8)</td><td>62.0 (45.0–69.0)</td><td>0.408c</td></tr><tr><td> LTT (sec)</td><td>59.8 (46.1–83.2)</td><td>32.3 (24.2–38.1)</td><td>0.429c</td></tr><tr><td> SDT (sec)</td><td>37.5 (33.3–42.3)</td><td>30.7 (27.1–34.5)</td><td>0.050a</td></tr><tr><td> WDT (score)</td><td>24.0 (22.0–27.0)</td><td>27.0 (24.5–29.3)</td><td>0.010a</td></tr><tr><td> Stroop-C (sec)</td><td>15.3 (13.5–18.4)</td><td>13.8 (9.9–15.8)</td><td>0.005a</td></tr><tr><td> Stroop-W (sec)</td><td>22.0 (18.5–26.1)</td><td>16.0 (13.5–18.5)</td><td>&lt; 0.001c</td></tr><tr><td> Stroop-I (sec)</td><td>31.5 (24.9–33.0)</td><td>24.3 (19.2–28.4)</td><td>0.003c</td></tr></tbody></table></div>a: k-independent samples nonparametric tests; b: chi square test; c: two-sample t testAbbreviations: A Doxorubicin, C Cyclophosphamide, T Docetaxel, E Epirubicin, SD standard deviation, E2 estradiol, FSH follicle stimulating hormone, LH luteinizing hormone, DST digit symbol test, MMSE Mini-mental state examination, LTT line tracing test, NCT-A number connection test A, SDT serial dotting test, SDS Self-Rating Depression Scale, SAS Self-Rating Anxiety Scale, Stroop-C Stroop colour test, Stroop-D Stroop word test, Stroop-I Stroop interference test, WDT Auditory verbal learning memory</transformed-table></extracted-table><extracted-table><table-id>Tab2</table-id><table-label>Table 2</table-label><table-caption>Blood Examination and Cognitive Assessment Results in Breast Cancer Group at Three Time Points</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table 2</label><caption><p>Blood Examination and Cognitive Assessment Results in Breast Cancer Group at Three Time Points</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="4">Median ± (IQRs)</th><th colspan="3"><italic>P</italic> value</th><th rowspan="2"><italic>F</italic> value</th><th rowspan="2"><italic>P</italic> value</th></tr><tr><th>Characteristic</th><th>t0</th><th>t1</th><th>t2</th><th>t0 vs t1</th><th>t0 vs t2</th><th>t1 vs t2</th></tr></thead><tbody><tr><td>E2 (pmol/L)</td><td>265.0 (112.3–391.8)</td><td>81.0 (52.0–125.0)</td><td>138.0 (84.5–195.0)</td><td>0.041</td><td>0.188</td><td>0.506</td><td>5.089</td><td>0.012<sup>c</sup></td></tr><tr><td>FSH (IU/L)</td><td>6.9 (3.9–40.1)</td><td>70.1 (10.3–89.9)</td><td>64.6 (19.9–112.2)</td><td>0.031</td><td>0.385</td><td>0.965</td><td>2.958</td><td>0.075<sup>c</sup></td></tr><tr><td>LH (IU/L)</td><td>7.3 (2.2–25.4)</td><td>34.5 (5.8–51.5)</td><td>7.6 (3.4–29.0)</td><td>0.662</td><td>0.926</td><td>0.156</td><td>3.344</td><td>0.106<sup>c</sup></td></tr><tr><td>Hemoglobin (g/L)</td><td>124.0 (110.0–134.0)</td><td>121.0 (113.3–126.0)</td><td>133.0 (123.5–142.0)</td><td>0.989</td><td>0.325</td><td>0.003</td><td>3.876</td><td>0.075<sup>c</sup></td></tr><tr><td>Fasting glucose (mmol/L)</td><td>5.2 (4.7–7.2)</td><td>5.4 (4.8–5.7)</td><td>5.4 (5.2–5.7)</td><td>0.677</td><td>0.523</td><td>0.832</td><td>0.215</td><td>0.808<sup>a</sup></td></tr><tr><td>Total cholesterol (mmol/L)</td><td>4.9 (4.3–5.7)</td><td>5.0 (4.5–5.4)</td><td>4.9 (4.7–5.2)</td><td>0.745</td><td>0.732</td><td>0.990</td><td>0.076</td><td>0.927<sup>c</sup></td></tr><tr><td>Triglycerides (mmol/L)</td><td>1.49 (0.9–3.0)</td><td>2.0 (1.44–3.70)</td><td>2.1 (1.90–2.70)</td><td>0.041</td><td>1.000</td><td>0.194</td><td>3.281</td><td>0.052<sup>a</sup></td></tr><tr><td>SAS (score)</td><td>29.0 (27.0–31.8)</td><td>32 (32.0–35.0)</td><td>27.0 (23.3–34.8)</td><td>0.186</td><td>0.659</td><td>0.098</td><td>1.548</td><td>0.228<sup>a</sup></td></tr><tr><td>SDS (score)</td><td>27.5 (24.5–32.0)</td><td>34.0 (33.0–34.0)</td><td>29.0 (24.0–41.5)</td><td>0.133</td><td>0.221</td><td>0.677</td><td>1.418</td><td>0.257<sup>c</sup></td></tr><tr><td>Stroop-C (sec)</td><td>15.3 (13.5–18.4)</td><td>14.4 (12.9–15.5)</td><td>14.4 (12.9–15.5)</td><td>0.480</td><td>0.493</td><td>0.985</td><td>0.340</td><td>0.714<sup>c</sup></td></tr><tr><td>Stroop-W (sec)</td><td>22.0 (18.5–26.1)</td><td>18.9 (17.1–20.1)</td><td>19.0 (14.4–19.6)</td><td>0.235</td><td>0.179</td><td>0.876</td><td>1.156</td><td>0.327<sup>c</sup></td></tr><tr><td>Stroop-I (sec)</td><td>31.5 (24.9–33.0)</td><td>29.0 (25.0–34.7)</td><td>24.0 (20.0–42.0)</td><td>0.999</td><td>0.992</td><td>0.991</td><td>0.001</td><td>0.999<sup>c</sup></td></tr><tr><td>NST (sec)</td><td>47.2 (39.8–62.0)</td><td>41.0 (39.5–51.5)</td><td>53.0 (40.0–71.0)</td><td>0.973</td><td>0.187</td><td>0.224</td><td>1.101</td><td>0.345<sup>c</sup></td></tr><tr><td>DST (score)</td><td>49.5 (34.0–61.8)</td><td>54.0 (45.0–64.0)</td><td>59.0 (43.0–60.0)</td><td>0.798</td><td>0.855</td><td>0.672</td><td>0.093</td><td>0.912<sup>c</sup></td></tr><tr><td>LTT (sec)</td><td>59.8 (46.1–83.2)</td><td>40.0 (28.2–48.5)</td><td>39.0 (30.8–56.0)</td><td>0.010</td><td>0.012</td><td>0.978</td><td>5.013</td><td>0.013<sup>c</sup></td></tr><tr><td>MMSE (score)</td><td>28.0 (27.0–29.5)</td><td>29.0 (28.0–29.5)</td><td>27.5 (26.3–29.8)</td><td>0.431</td><td>0.301</td><td>0.879</td><td>0.619</td><td>0.545<sup>c</sup></td></tr><tr><td>SDT (sec)</td><td>37.4 (33.3–42.3)</td><td>33.5 (30.9–38.7)</td><td>32.0 (27.8–36.9)</td><td>0.451</td><td>0.247</td><td>0.659</td><td>0.728</td><td>0.491<sup>c</sup></td></tr><tr><td>WDT (score)</td><td>24.0 (22.0–27.0)</td><td>21.0 (17.5–27.5)</td><td>18.0 (11.5–22.5)</td><td>0.278</td><td>0.002</td><td>0.082</td><td>5.595</td><td>0.008<sup>c</sup></td></tr></tbody></table><table-wrap-foot><p>a: k-independent samples nonparametric tests; c: two-sample t test</p><p><italic>Abbreviations</italic>: <italic>t0</italic> baseline assessment, <italic>t1</italic> one week after chemotherapy, <italic>t2</italic> six months after chemotherapy, <italic>SD</italic> standard deviation, <italic>E2</italic> estradiol, <italic>FSH</italic> follicle stimulating hormone, <italic>LH</italic> luteinizing hormone, <italic>DST</italic> digit symbol test, <italic>MMSE</italic> Mini-mental state examination, <italic>LTT</italic> line tracing test, <italic>NCT</italic> number connection test, <italic>SDT</italic> Serial dotting test, <italic>SDS</italic> Self-Rating Depression Scale, <italic>SAS</italic> Self-Rating Anxiety Scale, <italic>Stroop-C</italic> Stroop colour test, <italic>Stroop-W</italic> Stroop word test, <italic>Stroop-I</italic> Stroop interference test, <italic>WDT</italic> Auditory verbal learning memory</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Blood Examination and Cognitive Assessment Results in Breast Cancer Group at Three Time Points</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th colspan="4">Median ± (IQRs)</th><th colspan="3">P value</th><th rowspan="2">F value</th><th rowspan="2">P value</th></tr><tr><th>Characteristic</th><th>t0</th><th>t1</th><th>t2</th><th>t0 vs t1</th><th>t0 vs t2</th><th>t1 vs t2</th></tr></thead><tbody><tr><td>E2 (pmol/L)</td><td>265.0 (112.3–391.8)</td><td>81.0 (52.0–125.0)</td><td>138.0 (84.5–195.0)</td><td>0.041</td><td>0.188</td><td>0.506</td><td>5.089</td><td>0.012c</td></tr><tr><td>FSH (IU/L)</td><td>6.9 (3.9–40.1)</td><td>70.1 (10.3–89.9)</td><td>64.6 (19.9–112.2)</td><td>0.031</td><td>0.385</td><td>0.965</td><td>2.958</td><td>0.075c</td></tr><tr><td>LH (IU/L)</td><td>7.3 (2.2–25.4)</td><td>34.5 (5.8–51.5)</td><td>7.6 (3.4–29.0)</td><td>0.662</td><td>0.926</td><td>0.156</td><td>3.344</td><td>0.106c</td></tr><tr><td>Hemoglobin (g/L)</td><td>124.0 (110.0–134.0)</td><td>121.0 (113.3–126.0)</td><td>133.0 (123.5–142.0)</td><td>0.989</td><td>0.325</td><td>0.003</td><td>3.876</td><td>0.075c</td></tr><tr><td>Fasting glucose (mmol/L)</td><td>5.2 (4.7–7.2)</td><td>5.4 (4.8–5.7)</td><td>5.4 (5.2–5.7)</td><td>0.677</td><td>0.523</td><td>0.832</td><td>0.215</td><td>0.808a</td></tr><tr><td>Total cholesterol (mmol/L)</td><td>4.9 (4.3–5.7)</td><td>5.0 (4.5–5.4)</td><td>4.9 (4.7–5.2)</td><td>0.745</td><td>0.732</td><td>0.990</td><td>0.076</td><td>0.927c</td></tr><tr><td>Triglycerides (mmol/L)</td><td>1.49 (0.9–3.0)</td><td>2.0 (1.44–3.70)</td><td>2.1 (1.90–2.70)</td><td>0.041</td><td>1.000</td><td>0.194</td><td>3.281</td><td>0.052a</td></tr><tr><td>SAS (score)</td><td>29.0 (27.0–31.8)</td><td>32 (32.0–35.0)</td><td>27.0 (23.3–34.8)</td><td>0.186</td><td>0.659</td><td>0.098</td><td>1.548</td><td>0.228a</td></tr><tr><td>SDS (score)</td><td>27.5 (24.5–32.0)</td><td>34.0 (33.0–34.0)</td><td>29.0 (24.0–41.5)</td><td>0.133</td><td>0.221</td><td>0.677</td><td>1.418</td><td>0.257c</td></tr><tr><td>Stroop-C (sec)</td><td>15.3 (13.5–18.4)</td><td>14.4 (12.9–15.5)</td><td>14.4 (12.9–15.5)</td><td>0.480</td><td>0.493</td><td>0.985</td><td>0.340</td><td>0.714c</td></tr><tr><td>Stroop-W (sec)</td><td>22.0 (18.5–26.1)</td><td>18.9 (17.1–20.1)</td><td>19.0 (14.4–19.6)</td><td>0.235</td><td>0.179</td><td>0.876</td><td>1.156</td><td>0.327c</td></tr><tr><td>Stroop-I (sec)</td><td>31.5 (24.9–33.0)</td><td>29.0 (25.0–34.7)</td><td>24.0 (20.0–42.0)</td><td>0.999</td><td>0.992</td><td>0.991</td><td>0.001</td><td>0.999c</td></tr><tr><td>NST (sec)</td><td>47.2 (39.8–62.0)</td><td>41.0 (39.5–51.5)</td><td>53.0 (40.0–71.0)</td><td>0.973</td><td>0.187</td><td>0.224</td><td>1.101</td><td>0.345c</td></tr><tr><td>DST (score)</td><td>49.5 (34.0–61.8)</td><td>54.0 (45.0–64.0)</td><td>59.0 (43.0–60.0)</td><td>0.798</td><td>0.855</td><td>0.672</td><td>0.093</td><td>0.912c</td></tr><tr><td>LTT (sec)</td><td>59.8 (46.1–83.2)</td><td>40.0 (28.2–48.5)</td><td>39.0 (30.8–56.0)</td><td>0.010</td><td>0.012</td><td>0.978</td><td>5.013</td><td>0.013c</td></tr><tr><td>MMSE (score)</td><td>28.0 (27.0–29.5)</td><td>29.0 (28.0–29.5)</td><td>27.5 (26.3–29.8)</td><td>0.431</td><td>0.301</td><td>0.879</td><td>0.619</td><td>0.545c</td></tr><tr><td>SDT (sec)</td><td>37.4 (33.3–42.3)</td><td>33.5 (30.9–38.7)</td><td>32.0 (27.8–36.9)</td><td>0.451</td><td>0.247</td><td>0.659</td><td>0.728</td><td>0.491c</td></tr><tr><td>WDT (score)</td><td>24.0 (22.0–27.0)</td><td>21.0 (17.5–27.5)</td><td>18.0 (11.5–22.5)</td><td>0.278</td><td>0.002</td><td>0.082</td><td>5.595</td><td>0.008c</td></tr></tbody></table></div>a: k-independent samples nonparametric tests; c: two-sample t testAbbreviations: t0 baseline assessment, t1 one week after chemotherapy, t2 six months after chemotherapy, SD standard deviation, E2 estradiol, FSH follicle stimulating hormone, LH luteinizing hormone, DST digit symbol test, MMSE Mini-mental state examination, LTT line tracing test, NCT number connection test, SDT Serial dotting test, SDS Self-Rating Depression Scale, SAS Self-Rating Anxiety Scale, Stroop-C Stroop colour test, Stroop-W Stroop word test, Stroop-I Stroop interference test, WDT Auditory verbal learning memory</transformed-table></extracted-table><extracted-table><table-id>Tab3</table-id><table-label>Table 3</table-label><table-caption>Statistically Significant Differences of Within-network Functional Connectivity for Breast Cancer Group</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab3"><label>Table 3</label><caption><p>Statistically Significant Differences of Within-network Functional Connectivity for Breast Cancer Group</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Anatomic region (RSN)</th><th rowspan="2">Cluster voxel</th><th colspan="3">MNI Coordinates</th><th rowspan="2">F-score (peak value)</th></tr><tr><th>x</th><th>y</th><th>z</th></tr></thead><tbody><tr><td>Right superior frontal gyrus (ADMN)</td><td>17</td><td>15</td><td>36</td><td>48</td><td>22.892</td></tr><tr><td>Posterior cingulate (PDMN)</td><td>13</td><td>−12</td><td>−51</td><td>18</td><td>16.763</td></tr><tr><td>Left supplementary motor area (CN)</td><td>50</td><td>16</td><td>1</td><td>70</td><td>16.752</td></tr><tr><td>Right supplementary motor area (CN)</td><td>30</td><td>−9</td><td>−3</td><td>69</td><td>16.047</td></tr><tr><td>Left superior frontal gyrus (LFPN)</td><td>27</td><td>−15</td><td>30</td><td>48</td><td>19.190</td></tr><tr><td>Pars triangularis of right inferior frontal gyrus (RFPN)</td><td>14</td><td>45</td><td>31</td><td>26</td><td>18.939</td></tr><tr><td>Left orbital inferior frontal gyrus (SRN)</td><td>8</td><td>−24</td><td>27</td><td>−9</td><td>15.689</td></tr><tr><td>Right calcarine sulcus cortex (VN)</td><td>14</td><td>18</td><td>−72</td><td>15</td><td>12.241</td></tr></tbody></table><table-wrap-foot><p>Gaussian Random Field theory correction, voxel <italic>P</italic> value &lt; 0.001, cluster <italic>P</italic> value &lt; 0.05</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 3<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Statistically Significant Differences of Within-network Functional Connectivity for Breast Cancer Group</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Anatomic region (RSN)</th><th rowspan="2">Cluster voxel</th><th colspan="3">MNI Coordinates</th><th rowspan="2">F-score (peak value)</th></tr><tr><th>x</th><th>y</th><th>z</th></tr></thead><tbody><tr><td>Right superior frontal gyrus (ADMN)</td><td>17</td><td>15</td><td>36</td><td>48</td><td>22.892</td></tr><tr><td>Posterior cingulate (PDMN)</td><td>13</td><td>−12</td><td>−51</td><td>18</td><td>16.763</td></tr><tr><td>Left supplementary motor area (CN)</td><td>50</td><td>16</td><td>1</td><td>70</td><td>16.752</td></tr><tr><td>Right supplementary motor area (CN)</td><td>30</td><td>−9</td><td>−3</td><td>69</td><td>16.047</td></tr><tr><td>Left superior frontal gyrus (LFPN)</td><td>27</td><td>−15</td><td>30</td><td>48</td><td>19.190</td></tr><tr><td>Pars triangularis of right inferior frontal gyrus (RFPN)</td><td>14</td><td>45</td><td>31</td><td>26</td><td>18.939</td></tr><tr><td>Left orbital inferior frontal gyrus (SRN)</td><td>8</td><td>−24</td><td>27</td><td>−9</td><td>15.689</td></tr><tr><td>Right calcarine sulcus cortex (VN)</td><td>14</td><td>18</td><td>−72</td><td>15</td><td>12.241</td></tr></tbody></table></div>Gaussian Random Field theory correction, voxel P value &lt; 0.001, cluster P value &lt; 0.05</transformed-table></extracted-table><extracted-table><table-id>Tab4</table-id><table-label>Table 4</table-label><table-caption>Summary of Within-network Functional Connectivity for Breast Cancer Group at three time-points</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab4"><label>Table 4</label><caption><p>Summary of Within-network Functional Connectivity for Breast Cancer Group at three time-points</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="3">Median ± (IQRs)</th><th colspan="3"><italic>P</italic> value</th><th rowspan="2"><italic>F</italic> value</th><th rowspan="2"><italic>P</italic> value</th></tr><tr><th>t0</th><th>t1</th><th>t2</th><th>t0 vs t1</th><th>t0 vs t2</th><th>t1 vs t2</th></tr></thead><tbody><tr><td>ADMN</td><td>1.2 (0.7–1.8)</td><td>1.8 (1.4–1.8)</td><td>1.2 (0.8–1.7)</td><td>0.015</td><td>0.658</td><td>0.005</td><td>5.110</td><td>0.010</td></tr><tr><td>PDMN</td><td>0.8 (0.5–1.2)</td><td>1.2 (1.0–1.5)</td><td>1.0 (0.7–1.3)</td><td>0.001</td><td>0.270</td><td>0.012</td><td>7.321</td><td>0.002</td></tr><tr><td>LFPN</td><td>1.3 (1.2–2.0)</td><td>2.0 (1.6–2.3)</td><td>1.5 (1.1–1.9)</td><td>0.037</td><td>0.464</td><td>0.006</td><td>4.469</td><td>0.017</td></tr><tr><td>RFPN</td><td>2.0 (1.4–2.4)</td><td>2.5 (2.0–3.2)</td><td>2.0 (1.7–2.5)</td><td>0.006</td><td>0.489</td><td>0.034</td><td>4.518</td><td>0.016</td></tr><tr><td>CN</td><td>2.4 (1.4–2.9)</td><td>3.7 (2.5–4.9)</td><td>2.3 (1.7–2.9)</td><td>0.000</td><td>0.812</td><td>0.001</td><td>12.163</td><td>0.001</td></tr><tr><td>SRN</td><td>1.2 (0.9–1.7)</td><td>2.0 (1.2–2.2)</td><td>1.1 (0.7–1.7)</td><td>0.011</td><td>0.722</td><td>0.004</td><td>5.381</td><td>0.008</td></tr><tr><td>VN</td><td>2.1 (1.7–2.8)</td><td>1.5 (1.1–2.1)</td><td>2.2 (1.8–3.5)</td><td>0.123</td><td>0.087</td><td>0.002</td><td>5.503</td><td>0.007</td></tr></tbody></table><table-wrap-foot><p>t0, baseline assessment; t1, one week after chemotherapy; t2, six months after chemotherapy</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 4<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Summary of Within-network Functional Connectivity for Breast Cancer Group at three time-points</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="3">Median ± (IQRs)</th><th colspan="3">P value</th><th rowspan="2">F value</th><th rowspan="2">P value</th></tr><tr><th>t0</th><th>t1</th><th>t2</th><th>t0 vs t1</th><th>t0 vs t2</th><th>t1 vs t2</th></tr></thead><tbody><tr><td>ADMN</td><td>1.2 (0.7–1.8)</td><td>1.8 (1.4–1.8)</td><td>1.2 (0.8–1.7)</td><td>0.015</td><td>0.658</td><td>0.005</td><td>5.110</td><td>0.010</td></tr><tr><td>PDMN</td><td>0.8 (0.5–1.2)</td><td>1.2 (1.0–1.5)</td><td>1.0 (0.7–1.3)</td><td>0.001</td><td>0.270</td><td>0.012</td><td>7.321</td><td>0.002</td></tr><tr><td>LFPN</td><td>1.3 (1.2–2.0)</td><td>2.0 (1.6–2.3)</td><td>1.5 (1.1–1.9)</td><td>0.037</td><td>0.464</td><td>0.006</td><td>4.469</td><td>0.017</td></tr><tr><td>RFPN</td><td>2.0 (1.4–2.4)</td><td>2.5 (2.0–3.2)</td><td>2.0 (1.7–2.5)</td><td>0.006</td><td>0.489</td><td>0.034</td><td>4.518</td><td>0.016</td></tr><tr><td>CN</td><td>2.4 (1.4–2.9)</td><td>3.7 (2.5–4.9)</td><td>2.3 (1.7–2.9)</td><td>0.000</td><td>0.812</td><td>0.001</td><td>12.163</td><td>0.001</td></tr><tr><td>SRN</td><td>1.2 (0.9–1.7)</td><td>2.0 (1.2–2.2)</td><td>1.1 (0.7–1.7)</td><td>0.011</td><td>0.722</td><td>0.004</td><td>5.381</td><td>0.008</td></tr><tr><td>VN</td><td>2.1 (1.7–2.8)</td><td>1.5 (1.1–2.1)</td><td>2.2 (1.8–3.5)</td><td>0.123</td><td>0.087</td><td>0.002</td><td>5.503</td><td>0.007</td></tr></tbody></table></div>t0, baseline assessment; t1, one week after chemotherapy; t2, six months after chemotherapy</transformed-table></extracted-table></extracted-tables-set>